| Literature DB >> 20738017 |
Christopher D Aluise1, Rukhsana Sultana, Jitbangjong Tangpong, Mary Vore, Daret St Clair, Jeffrey A Moscow, D Allan Butterfield.
Abstract
Doxorubicin (ADRIAMYCIN, RUBEX) is a chemotherapeutic agent that is commonly administered to breast cancer patients in standard chemotherapy regimens. As true of all such therapeutic cytotoxic agents, it can damage normal, noncancerous cells and might affect biochemical processes in a manner that might lead to, or contribute to, chemotherapy-induced cognitive deficits when administered either alone or in combination with other agents.Entities:
Mesh:
Substances:
Year: 2010 PMID: 20738017 DOI: 10.1007/978-1-4419-6306-2_19
Source DB: PubMed Journal: Adv Exp Med Biol ISSN: 0065-2598 Impact factor: 2.622